Literature DB >> 18926675

Human health risk assessment for peroxisome proliferators: more than 30 years of research.

Marco Fidaleo1.   

Abstract

Substances like gemfibrozil, clofibrate and fenofibrate, widely used in human care for their hypolipidemic effects, belong to a larger class of chemicals called peroxisome proliferators (PPs). PPs, by binding and activing the peroxisome proliferator-activated receptor alpha (PPARalpha), modulate gene involved in lipid homeostasis both in human and in rodent. In a different way, long term administration of PPs results in hepatocarcinogenesis only in rodent. Although the phenomenon is known since more than 30 years, the exact mechanism is not well understood and the human health risks are not established. In this mini-review is inspected the major findings done in the different species and illustrates the possible doubts for human health by the use of PPs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926675     DOI: 10.1016/j.etp.2008.09.002

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  5 in total

1.  Clofibrate as an Adjunct to Phototherapy for Unconjugated Hyperbilirubinemia in Term Neonates.

Authors:  Prasad Kumar; B Adhisivam; B Vishnu Bhat
Journal:  Indian J Pediatr       Date:  2017-05-17       Impact factor: 1.967

2.  E2/ERβ Inhibits PPARα to Regulate Cell-Proliferation and Enhance Apoptosis in Hep3B-Hepatocellular Carcinoma.

Authors:  Shu Nu Chang-Lee; Hsi-Hsien Hsu; Marthandam Asokan Shibu; Tsung-Jung Ho; Chih-Hao Tsai; Ming-Cheng Chen; Chuan-Chou Tu; Vijaya Padma Viswanadha; Wei- Wen Kuo; Chih-Yang Huang
Journal:  Pathol Oncol Res       Date:  2016-10-18       Impact factor: 3.201

3.  Role of PPARα in Hepatic Carbohydrate Metabolism.

Authors:  Annelies Peeters; Myriam Baes
Journal:  PPAR Res       Date:  2010-09-30       Impact factor: 4.964

4.  Connexin-based signaling and drug-induced hepatotoxicity.

Authors:  Michaël Maes; Mathieu Vinken
Journal:  J Clin Transl Res       Date:  2017-02-12

5.  Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.

Authors:  Jonathan D Roth; Sanne S Veidal; Louise K D Fensholdt; Kristoffer T G Rigbolt; Romeo Papazyan; Jens Christian Nielsen; Michael Feigh; Niels Vrang; Mark Young; Jacob Jelsing; Luciano Adorini; Henrik H Hansen
Journal:  Sci Rep       Date:  2019-06-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.